Nephro-Urology Monthly

Published by: Kowsar

Serum Leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?

David Johnson Department of Nephro , * and David Johnson 2 , *
Authors Information
1 Department of Nephro, Brisbane, Australia
2 Department of Nephrology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Corresponding Authors:
Article information
  • Nephro-Urology Monthly: December 01, 2011, 4 (1); 333-335
  • Published Online: December 18, 2011
  • Article Type: Editorial
  • Received: October 6, 2011
  • Revised: October 11, 2011
  • Accepted: October 21, 2011
  • DOI: 10.5812/kowsar.22517006.2626

To Cite: Johnson D, Johnson D. Serum Leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?, Nephro-Urol Mon. 2011 ; 4(1):333-335. doi: 10.5812/kowsar.22517006.2626.

Copyright © 2011, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. lameire N, Van Biesen W. Epidemiology of peritoneal dialysis: a story of believers and nonbeliever. Nat Rev Nephrol. 2010; 6(2): 75-82[DOI][PubMed]
  • 2. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl. 2006; 103-11
  • 3. Davies SJ, Phillips l, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001; 12(5): 1046-51[PubMed]
  • 4. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int. 1997; 17(1)[PubMed]
  • 5. Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther. 1998; 5(3): 179-84[PubMed]
  • 6. Pecoits-Filho R, Stenvinkel P, heimburger o, lindholm B. Beyond the membrane-the role of new PD solutions in enhancing global biocompatibility. Kidney Int Suppl. 2003; 88-32[DOI][PubMed]
  • 7. Witowski J, Jorres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int. 2005; 25-4[PubMed]
  • 8. Schambye HT. Effect of different buffers on the biocompatibility of CAPD solutions. Perit Dial Int. 1996; 16-6[PubMed]
  • 9. Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE, et al. . BIoKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]. BMC Nephrol. 2004; 5: 14[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments